-
2 weeks ago | 
theaustralian.com.au | damon johnston |Greg Sheridan |Yoni Bashan |Nick Evans
StockheadTylah Tully chats with Pioneer (ASX:PLN) CEO Michael Beven about the company’s new uranium focus across multiple jurisdictions. At the Skull Creek project in Colorado, Pioneer has initiated a two-phase soil sampling program targeting multiple high-priority zones. It is also focused on the Warmbad uranium project in Namibia, broadening its geological and economic potential across the company's portfolio. Watch the video to learn more.
-
2 weeks ago | 
theaustralian.com.au | Greg Sheridan |Yoni Bashan |Sarah Ison |Rhiannon Down
DY6 spots visible rutile while sampling Central Rutile project in CameroonRegion emerging as globally significant rutile provinceLab results pending and auger and grab sampling plannedSpecial Report: DY6 Metals has spotted natural rutile throughout its Central Rutile tenement package in Cameroon, Africa.
-
4 weeks ago | 
theaustralian.com.au | Ros Thomas |Greg Sheridan |Chris Uhlmann |Ben Packham
StockheadStockhead’s Tylah Tully breaks down the latest from West Coast Silver (ASX:WCE), who have started drilling to test extensions of known high-grade mineralisation at its Elizabeth Hill project in Western Australia. This is West Coast's maiden campaign at the project after only recently acquiring it, but the company believes there could be a lot of silver at play. Watch the video for more.
-
1 month ago | 
theaustralian.com.au | Greg Sheridan |Geordie Gray |James Kirby |Ellie Dudley
Perpetual Resources’ soil sampling extends strike of lithium-bearing pegmatite at main Igrejinha prospect in Brazil to >1.4km First-pass sampling identified new anomaly about 2.3km to the southeast within highly prospective corridor Preparations well advanced for maiden drilling of Igrejinha prospect to start in early June Special Report: Soil sampling at Perpetual Resources’ Igrejinha project in Brazil’s famed Lithium Valley in the Minas Gerais state has identified a broad and coherent...
-
1 month ago | 
theaustralian.com.au | Greg Sheridan |James Kirby |Geordie Gray |Greg Brown
StockheadStockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully unpacks Titanium Sands (ASX:TSL) latest news after they were awarded one year retention licences for the company's Sri Lankan heavy mineral sands project, allowing the progression to environmental studies. Watch the video to find out the latest. While Titanium Sands is a Stockhead advertiser, it did not sponsor this content.
-
1 month ago | 
theaustralian.com.au | Geoff Chambers |Sarah Ison |Greg Sheridan |Janet Albrechtsen
AXL reports more high-grade rare earths results at Caldas project in BrazilProject in same neighbourhood as MEI and VMM discoveriesCompany confident of expanding REE footprint in the regionSpecial Report: Axel REE says auger drilling at its Caldas project in Brazil continues to return high grade rare earth elements including high-value neodymium and praseodymium (NdPr), and dysprosium and terbium (DyTb).
-
1 month ago | 
theaustralian.com.au | Robert Gottliebsen |Ellie Dudley |John Ferguson |Greg Sheridan
EBR Systems has applied for a Transitional Pass-Through (TPT) reimbursement scheme for its WISE CRT System through the US Centers for Medicare & Medicaid Services (CMS)The application is for outpatients, following on from a recommendation from the CMS that inpatients be eligible for the New Technology Add-On PaymentThe criteria are the same for both schemes, giving EBR high confidence they will be approved.
-
2 months ago | 
theaustralian.com.au | Peta Credlin |Liam Mendes |Yoni Bashan |Greg Sheridan
StockheadRegenerative medicine developer Orthocell (ASX:OCC) has appointed the first four US distributors for its flagship nerve repair product Remplir. The appointments follow FDA clearance for Remplir which landed earlier this month, and Orthocell are expecting first sales in the US very soon. Today, the US' nerve repair market is valued at US$1.6 billion. Orthocell will tap this market through distributors in Michigan, Virginia, Colorado and Indiana.
-
2 months ago | 
theaustralian.com.au | Cameron Stewart |Greg Sheridan |Christine Middap |Bernard Salt
Special Report: Chimeric antigen receptor (CAR-T) cell therapy is a rapidly growing frontier in cancer research, with Australian biotech Arovella Therapeutics at the forefront and working to overcome limitations of this promising treatment.
-
2 months ago | 
theaustralian.com.au | Greg Sheridan |Michael McKenna |Lydia Lynch |Henry Ergas
Funding to support Phase III clinical trials for diabetic foot infections and acute bacterial skin and skin structure infectionsPrivate Australian-based investor has subscribed for $5 million shares via a placementA$10.8 million entitlement offer has been launched at $0.28 per shareSpecial Report: Targeting first revenue in 2026, Recce will use new funds of up to $15.8m to support a Phase III registrational topical clinical trial for its diabetic foot infection (DFI) treatment in Indonesia.
